Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ABBV-291 |
| Synonyms | |
| Therapy Description |
ABBV-291 is an antibody-drug conjugate (ADC) targeting CD79B, which potentially induces antitumor activity (J Clin Oncol 2025 43: 16_suppl, TPS7093). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ABBV-291 | ABBV291|ABBV 291 | ABBV-291 is an antibody-drug conjugate (ADC) targeting CD79B, which potentially induces antitumor activity (J Clin Oncol 2025 43: 16_suppl, TPS7093). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06667687 | Phase I | ABBV-291 | Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma | Recruiting | USA | ISR | GBR | AUS | 1 |